Partnering Strategy

7TM Pharma is strategically focused on its development as a 7TM Receptor Powerhouse, i.e. the further exploitation of our strong drug discovery engine targeting 7TM receptors, and the effective management of the process from drug target to proof of concept in man.

We have chosen metabolic disorders as primary therapeutic focus and will in this area develop selected programs up to proof of concept in man (Phase II) prior to partnering them with pharmaceutical companies with an established franchise in the respective therapeutic area. Staying focused on maximizing the value of our know-how and ongoing activities, 7TM Pharma will opportunistically pursue programs in other therapeutic indications (e.g. inflammation), but partner these during late discovery or early pre-clinical development with partners having the specific therapeutic expertise and development/commercialization resources. This decision reflects a focus on our core competence to create medium-term value through drug discovery and early development of a larger number of projects, thus freeing resources for generation of further drug discovery projects from our discovery engine and ensuring a focused in-house pipeline. A balanced risk profile is achieved by working on both, classical small molecule programs as well as selected peptide programs, depending on the nature of the drug target, its validation and chemical tractability, as well as the therapeutic indication in question.